erythropoiesis-stimulating agent


Also found in: Dictionary, Thesaurus, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.

erythropoiesis-stimulating agent

Abbreviation: ESA.
Any drug that binds to cellular receptors for erythropoietin and encourages red blood cell production by the bone marrow. Members of this class of drugs, which include epoietin and darbopoietin, are used to treat anemia, e.g., in patients with chronic kidney disease, cancer, or aplastic anemia. ESAs are used as an alternative to red blood cell transfusions. Potential side effects of treatment include high blood pressure and an increased risk of blood clots.
See also: agent
References in periodicals archive ?
Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.
Possible reasons for switching a patient between erythropoiesis-stimulating agents may include patient preference, injection site pain, hypersensitivity to one of the erythropoiesis-stimulating agents, stability/storage, dosing interval, lack of response to one of the erythropoiesis-stimulating agents and the support provided by the manufacturer.
Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Impact of Frequent Hemoglobin Measurement and Erythropoiesis-Stimulating Agent Dose Titration on Hemoglobin Stability in Dialysis (Szczech, et al.
Her hemoglobin (Hb) levels had been steadily declining despite escalating doses of an erythropoiesis-stimulating agent (ESA).
nephrologists about their current awareness, trial and usage of Affymax/Takeda's Omontys (peginesatide), an erythropoiesis-stimulating agent (ESA) recently approved by the U.
Erythropoiesis-Stimulating Agent (ESA) Dose Recovery Following Hospitalization of End Stage Renal Disease (ESRD) Patients.
Omontys (peginesatide) is a new once-monthly erythropoiesis-stimulating agent (ESA) for anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
LIFE Biosystems announced today that is has been chosen to present its breakthrough findings related to erythropoiesis-stimulating agent (ESA) treatment at this year's annual meeting for the American Association for Cancer Research.
The poster presentation highlighted the unique mechanism of action and selective profile of LG5640, a novel oral EPO receptor agonist being developed as a more convenient and safer treatment alternative to current erythropoiesis-stimulating agent therapies (ESAs).
Amgen's solid margin has been supported by significant restructuring activities in August 2007 following a drastic demand decline of the company's once top-selling product, the erythropoiesis-stimulating agent (ESA) Aranesp.

Full browser ?